Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The agency’s evolving regulatory stance was formally outlined in an article published in the New England Journal of Medicine (NEJM) on Wednesday.
Senior FDA Officials Author the NEJM Piece
The article was authored by prominent figures within the FDA’s Center for Drug Evaluation and Research (CDER). Among the authors are Michael Davis, who was appointed as CDER’s permanent director earlier in the same week, Teresa Buracchio, Director of the Office of Neuroscience within the Office of New Drugs at CDER, and Tiffany Farchione and Bernard Fischer, who lead the Division of Psychiatry within the Office of Neuroscience.
The publication follows the FDA’s release of its final guidance on clinical investigations of psychedelic drugs in July — a document that came three years after the agency had issued a draft version for public comment.
Acknowledging Unmet Need in Mental Health
The officials acknowledged the significant prevalence and economic burden of mental health disorders, specifically highlighting major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). They were candid about the limitations of currently available treatments.
“[FDA] recognizes that although some people benefit from available treatment options, for others our current medications are not enough,” the authors wrote. “The FDA is committed to meeting this moment with the urgency it deserves. Through innovation and by leveraging existing programs, we can begin to address the unmet need for new and better treatments.”
Breakthrough Therapy Designations Granted to Investigational Psychedelics
The officials noted that the FDA has already granted breakthrough therapy designation to several investigational psychedelic compounds. This designation enables more intensive guidance from the agency, more frequent opportunities for developer meetings with FDA officials, and the possibility of a rolling review process.
Among the compounds that have received such designations are Definium Therapeutics’ LSD-derivative DT120, which recently received its second breakthrough designation, and Cybin Inc’s CYB003, a deuterated psilocybin analog. Despite these designations, no psychedelic drug has yet received FDA approval for any indication.
In 2024, the agency rejected Lykos Therapeutics’ — now operating as Resilient Pharmaceuticals — MDMA-assisted therapy for PTSD, despite the compound having received the first breakthrough therapy designation ever granted for a psychedelic drug back in 2017.
Final Guidance Offers Flexible Framework for Clinical Trials
The recently finalized guidance was highlighted by the CDER officials as offering a flexible and adaptive approach to psychedelic drug development. In their own words: “The guidance builds on the agency’s experience with drug development programs and incorporates relevant input from the scientific and patient community to address the distinct methodologic challenges in psychedelic clinical trial design — particularly issues around blinding, selection of control, and assessment of the durability of treatment effects.”
Addressing the Challenge of Unblinding
One of the most significant methodological hurdles in psychedelic clinical trial design is the issue of unblinding. The “pronounced and recognizable” treatment effects of these drugs can cause both patients and clinical investigators to become “functionally unblinded” during a study, undermining the integrity of traditional placebo-controlled trial designs.
To address this, the FDA has indicated openness to trial designs that use an active comparator rather than an inert placebo — either to mask whether a participant is receiving the investigational drug or by comparing the study drug to a lower dose of the same compound. However, the officials also noted that the agency may still require a placebo-controlled trial in some instances, as comparison to an inactive placebo helps determine whether adverse events are attributable to the investigational drug itself.
Approval Based on Clinically Meaningful Duration of Efficacy
The officials confirmed that the FDA is also open to approving psychedelics for intermittent or as-needed use, noting a flexible position on the timeline of demonstrated efficacy. “The FDA is receptive to granting initial approval based on evidence of efficacy over a clinically meaningful duration (e.g., 12 weeks), in conjunction with a longer-term preliminary assessment of the need for and safety of treatment with additional doses (e.g., continuing blinded follow-up for 12 months),” they wrote, adding that questions about dose interval and continued efficacy could be resolved in the post-approval phase.
Safety Requirements and Post-Marketing Obligations
Given the risks associated with psychedelic compounds, the FDA officials indicated that a risk evaluation and mitigation strategy (REMS) — potentially incorporating elements to assure safe use (ETASU) — along with additional post-marketing studies, may be required as conditions for approval. These measures reflect the agency’s commitment to balancing therapeutic access with patient safety in the evolving landscape of psychedelic drug development.
